Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate ...( -- New Phase 3 trial of Genasense(R)...),Health

-- New Phase 3 trial of Genasense(R) seeks to confirm benefit in melanoma

-- New IND filed for clinical-stage product to treat bone disease -- Company regains compliance for NASDAQ Global Markets listing; Genta

common stock to resume trading under "GNTA" symbol in August 2007 -- Named-patient/compassionate-use program for Genasense will continue

during Phase 3 trial

-- Appeal of FDA decision on Genasense NDA in CLL pending

BERKELEY HEIGHTS, N.J., Aug. 7 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTAD) today announced financial results and corporate highlights for the second quarter ended June 30, 2007.

"Over the past several months, we critically examined our development programs and have concluded that our assets and employees represent a significant value opportunity for shareholders," commented Dr. Raymond P. Warrell, Jr., Genta's Chairman and Chief Executive Officer. "Our lead compound, Genasense(R), has demonstrated improved outcomes for patients with CLL and melanoma, and we plan to pursue plans that will seek global regulatory approvals of this drug. In addition to developing dosing schedules of Genasense that may simplify its administration, we have added a new clinical- stage compound with the announcement of an IND filing for an orally available gallium product to treat accelerated bone loss. We plan to continue ongoing efforts to further diversify the Company's portfolio and leverage our expertise in clinical research."

New Randomized Phase 3 Trial of Genasense plus Dacarbazine in Advanced Melanoma

The Company has announced plans to initiate a new Phase 3 trial, now known as AGENDA: "A Randomized Controlled Trial
'/>"/>

SOURCE Genta Incorporated Copyright©2007 PR Newswire.

0 GOOD